RxDoctor Payments Data

George Carayannopoulos, MD

Clinical Cardiac Electrophysiology · Galveston, TXNPI 1740349471

Payments from drug & device makers

$4,382in general payments, 2019–2025

Across 136 payments — averaging $32.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$987
  • Abbott$715
  • Johnson & Johnson$232
  • Biosense Webster, Inc.$133
  • Amgen$83
  • plus $412 from 11 others

What the payments were for

  • Travel & lodging$74017%
  • Food & beverage$3,64183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,382 in reported general payments places this provider in the 5th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$91,231
Medicare patients
348
Services billed
1,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban374$437,682
MultaqDronedarone Hcl70$92,893
XareltoRivaroxaban63$59,151
EntrestoSacubitril/Valsartan15$21,915
Metoprolol Succinate349$7,967
Digoxin66$2,071
Amiodarone Hcl97$1,450
Bisoprolol Fumarate54$1,370
Ranolazine ErRanolazine16$1,328
Flecainide Acetate32$1,224
Diltiazem 24hr Er (Xr)Diltiazem Hcl25$1,222
Dilt-XrDiltiazem Hcl27$1,110
Atorvastatin Calcium97$923
Losartan Potassium65$846
SotalolSotalol Hcl35$757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$437,682374 claims
Sanofi-aventis U.S. LLCMultaq$67$92,89370 claims
Johnson & JohnsonXarelto$232$59,15163 claims
NovartisEntresto$23$21,91515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Galveston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →